Skip to content

Clinical Outcome at 5 Years After Implantation of the Liberty677MY Multifocal Intraocular Lens

Clinical Outcome at 5 Years After Implantation of Medicontur Multifocal Intraocular Lens Liberty 677MY: Visual Outcomes, Patients' Satisfaction, YAG Capsulotomy Rate

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04220255
Enrollment
50
Registered
2020-01-07
Start date
2019-11-01
Completion date
2020-12-31
Last updated
2023-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

The study will assess visual outcomes, light disturbances and patients' satisfaction after implantation with the Liberty677MY multifocal IOL, as well as protection of PCO development within 5 year follow-up.

Detailed description

The Liberty677MY multifocal IOL is designed for restoring near, intermediate and distance vision. The technology of Liberty 677MY is based on the elevated phase shift technology (patent pending). Previous evaluations showed the strength of studied IOL both in laboratory and clinical conditions. Patients will be examined 5 years after implantation. The examination will include the measurement of the best corrected distance, intermediate and near visual acuity (assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) charts), intraocular pressure (contact Goldman tonometry), biomicroscopic and fundocsopic examination, contrast sensitivity (CSV-1000), defocus curve, reading capability, pupilometry in different light conditions and PCO evaluation, Nd:YAG capsulotomy rate, photo-documentation of anterior segment. YAG capsulotomy will be indicated in case of posterior capsule opacification (PCO). The criteria for YAG capsulotomy will be visual acuity decreased 2 or more lines when using (ETDRS) charts. Details of all related and unrelated complications will be documented, including severity, time of onset, specific treatment and clinical outcome. The investigators will also record whether the capsulorhexis is on or partially off the optic.

Interventions

DEVICELiberty677MY Multifocal IOL

multifocal intraocular lens (IOL)

Sponsors

Medicontur Medical Engineering Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 86 Years
Healthy volunteers
No

Inclusion criteria

* pseudophakic patients implanted with Liberty 677MY in 2014-2015 during the study under the ethical approval: 059823/2014/OTIG

Exclusion criteria

* diabetic retinopathy * iris neovascularisation * serious intraoperative complications * congenital eye abnormality * glaucoma * pseudoexfoliation syndrome * amblyopia * uveitis * long-term anti-inflammatory treatment * AMD (advanced AMD) * retinal detachment * prior ocular surgery in personal medical history (except cataract surgery aiming the implantation of the multifocal IOL) * previous laser treatment * corneal diseases * severe retinal diseases (dystrophy, degeneration) * severe myopia (if required IOL power is lower than 10 D) * inadequate visualization of the fundus on preoperative examination * patients deemed by the clinical investigator because of any systemic disease. * pregnancy * eye trauma in medical history * current use of systemic steroids or topical ocular medication * preoperative smaller pupil size of 6 mm under topical mydriasis * kappa angle \>5°

Design outcomes

Primary

MeasureTime frameDescription
Contrast Sensitivity CSV-10005 years after implantationBinocular Assessment of contrast sensitivity at threshold using the Contrast sensitivity vision (CSV) CSV-1000 in photopic and mesopic conditions with or without glare.
Uncorrected Decimal VA (6 m)5 years after implantationVisual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 6 meters (m) using Early Treatment Diabetic Retinopathy ( ETDRS) charts and assessed in logarithm of the minimum angle of resolution (LogMAR).
Uncorrected Decimal VA (60 cm)5 years after implantationVisual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 60 centimeters (cm) using ETDRS charts, assessed in LogMAR.
Uncorrected Decimal VA (40 cm)5 years after implantationVisual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 40 centimeters (cm) using ETDRS charts, assessed in LogMAR.
Corrected Decimal VA (6 m)5 years after implantationVisual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 6 meters (m) using ETDRS charts, assessed in LogMAR.
Corrected Decimal VA (60 cm)5 years after implantationVisual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 60 centimeters (cm) using ETDRS charts , assessed in LogMAR.
Corrected Decimal VA (40 cm)5 years after implantationVisual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 40 centimeters (cm) using ETDRS charts, assessed in LogMAR.
Defocus Curve Profiles5 years after implantationVisual acuity measurement (assessed in logarithm of the minimum angle of resolution (LogMAR)) taken with different levels of optical defocus was tested monocularly (each eye separately) and binocularly (both eyes together).

Secondary

MeasureTime frame
Posterior capsule opacification (PCO) rate5 years after implantation

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026